Relationship between response to colchicine treatment and MDR1 polymorphism in familial mediterranean fever Patients

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 2, 2014, Pages 73-76

  Uludag, Ahmet ^a   Silan, Coskun ^b   Atik, Sinem ^a   Akurut, Cisem ^a   Uludag, Aysegul ^b   Silan, Fatma ^a   Ozdemir, Ozturk ^a  

^a University of Onsehz Mart Canakkale   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DNA; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; FAMILIAL MEDITERRANEAN FEVER; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; REAL TIME POLYMERASE CHAIN REACTION;

ALLELES; AMINO ACID SUBSTITUTION; COLCHICINE; CYTOSKELETAL PROTEINS; DNA MUTATIONAL ANALYSIS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84893815609     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0293     Document Type: Article

References (31)

1. Allabi AC, Horsmans Y, Issaoui B, Gala JL (2005) Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 61:97-102.
2. Ambudkar SV, Dey S, Hrycyna CA, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
3. Ameyaw MM, Regateiro F, Li T, et al. (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11: 217-221.
4. Andreu JM, Timasheff SN (1982) Interaction of tubulin with single ring analogue of colchicine. Biochemistry 21:534-543.
5. Ar?soy N, Kasapcopur O, Sever L, et al. (1997) Familial Mediterranean fever in Turkish children. In: First International Conference on Familial Mediterranean Fever Proceedings Book, Freund, London and Tel Aviv, pp. 168-172.
6. Ben-Chetrit E, Levy M (1998) Familial Mediterranean Fever. Lancet 351:659-664.
7. CalcagnoAM, KimIW,Wu CP, et al. (2007)ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv 4:324-333.
8. Callaghan R, Crowley E, Potter S, et al. (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48:365-378.
9. Caner JEZ (1965) Colchicine inhibition of chemotaxis. Arthritis Rheum 8:757-764.
10. Chen J, Chen L, Mao N, Liu Y (2012) Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol Int 32:3127-3130.
11. Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860-871.
12. Hoffmeyer S, Burk O, von Richter, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
13. Horinouchi M, Sakaeda T, Nakamura T, et al. (2002) Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: Functional relevance to pharmacokinetics of digoxin. Pharm Res 19:1581-1585.
14. John C. Mulley (1999) The genetic basis for periodic fever. Am J Hum Genet 64:939-942.
15. Kastner DL, Aksentijevich I (2004) Intermitant and periodic arthiritis syndromes. Arthritis and Allied Conditions. In: Koopman WJ, Moreland LW (eds) Textbook of Rhemotology, 15th ed. Williams & Wilkins, Philadelphia, pp. 1411-1461.
16. Lee SS, Kim SY, Kim WY, et al. (2005) MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit 27:531-535.
17. Li X, Li JP, Yuan HY, et al. (2007) Recent advances in P-glycoprotein- mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol 29:607-617.
18. Livneh A, Langevitz P, Zemer D, et al. (1996) The changing face of Familial Mediterranean Fever. Semin Arth Rheum 26:612-627.
19. Mansfield E, Chae JJ, Komarow HD, et al. (2001) The Familial Mediterranean Fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 98:851-859.
20. Molad Y, Reibman J, Levin RI (1992) A new mode of action for an old drug: colchicine decreases surface expression of adhesion molecules on both neutrophils (PMNs) and endothelium (abstract). Arthritis Rheum 35(Suppl):S35.
21. Niel E, Scherrmann JM (2006) Colchicine today. Joint Bone Spine 73:672-678.
22. Ozen F, Silan C, Uludag A, et al. (2011) Association between ABCB1 (MDR1) gene 3435 C T polymorphism and colchicine unresponsiveness of FMF patients. Ren Fail 33:899-903.
23. Ru stemoglu A, Gumus-Akay G, Yigit S, et al. 2011 Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial Mediterranean fever. Genet Mol Res 10 3411-3420
24. Saatci U, Ozen S, et al. (1997) Familial Mediterranean Fever in children; report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:819-823.
25. Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391-414.
26. Saricaoglu H, Yilmaz M, Karkucak M, et al. (2011) Investigation of ABCB1 gene polymorphism with colchicine response in Behcets disease. Genet Mol Res 10:1-6.
27. Schwab M, Eichelbaum M, Fromm MF, et al. (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307.
28. Shukla S, Wu CP, Ambudkar SV (2008) Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Exp Opin Drug Metab Toxicol 4:205-223.
29. Turgut G, Kurt E, Sengul C, et al. (2009) Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol Biol Rep 36:495-499.
30. Wallace SL (1974) Colchicine. Semin Arthritis Rheum 3:369-381.
31. Yuan H, Li X, Wu J, Li J, Qu X, et al. (2008) Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr Med Chem 15:470-476.